News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

VIVUS, Inc. (VVUS), Orexigen Therapeutics, Inc. (OREX) Stock Climb Ahead on Highly Anticipated FDA Decision



7/17/2012 8:14:50 AM

Shares of Vivus Inc. (US:vvus) jumped 5% to $28.63 Monday in anticipation that the U.S. Food and Drug Administration will soon approve its diet drug Qnexa. The FDA is scheduled to issue a decision by the end of Tuesday. Also gaining were shares of Orexigen Therapeutics (US:orex), up 7%. Orexigen announced last week that a clinical trial requested by the FDA for approval of its diet-drug candidate Contrave was ahead of schedule. Orexigen hopes to now have early results available by the end of 2013, rather than June 2014.

Read at Market Watch
Read at BusinessWeek
Read at Seeking Alpha
Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES